- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Hong Kong Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
15
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
15 companies
Hansoh Pharmaceutical Group
Market Cap: HK$188.9b
An investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China.
3692
HK$31.94
7D
-5.2%
1Y
1.4%
Innovent Biologics
Market Cap: HK$150.1b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$89.70
7D
2.2%
1Y
11.4%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$110.8b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$516.50
7D
3.5%
1Y
51.9%
Akeso
Market Cap: HK$87.2b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$97.25
7D
-5.0%
1Y
-14.1%
WuXi XDC Cayman
Market Cap: HK$75.0b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$60.30
7D
-2.3%
1Y
31.1%
RemeGen
Market Cap: HK$70.9b
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
9995
HK$84.10
7D
-4.2%
1Y
33.1%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$46.5b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$52.20
7D
16.5%
1Y
146.8%
3SBio
Market Cap: HK$42.5b
An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.
1530
HK$18.07
7D
-7.6%
1Y
-28.2%
Genscript Biotech
Market Cap: HK$28.9b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$13.84
7D
1.7%
1Y
-7.4%
Fujian Haixi Pharmaceuticals
Market Cap: HK$15.6b
Engages in research and development, production, and sale of pharmaceutical products in China.
2637
HK$205.40
7D
3.0%
1Y
n/a
CanSino Biologics
Market Cap: HK$9.5b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$23.42
7D
-3.8%
1Y
-37.0%
Luye Pharma Group
Market Cap: HK$7.6b
Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally.
2186
HK$1.92
7D
-5.4%
1Y
-43.2%
Frontage Holdings
Market Cap: HK$2.2b
Provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.11
7D
13.3%
1Y
0.9%
Essex Bio-Technology
Market Cap: HK$1.6b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$2.84
7D
-3.4%
1Y
-37.4%
Wai Yuen Tong Medicine Holdings
Market Cap: HK$345.5m
An investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong.
897
HK$0.29
7D
3.6%
1Y
-3.3%